Objective: To compare the incidence in postsurgical persistent pain following breast cancer surgery in women receiving intravenous lidocaine compared to saline using validated pain instruments in accordance with the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) recommendations.
INTRODUCTION
It is estimated that persistent postsurgical pain affects 15% to 60% of patients undergoing surgical procedures, and its incidence varies with the surgical procedure. [1] [2] [3] Multimodal analgesia approaches have been demonstrated to reduce opioid consumption, improve pain management, and reduce postoperative opioidinduced complications. 4, 5 The development of chronic pain (> 3 months) has been linked to the intensity of perioperative pain; therefore, it is conceivable that preemptive multimodal analgesic strategies may also reduce the development of chronic postsurgical pain. [6] [7] [8] Systemic lidocaine is considered an efficacious multimodal strategy to reduce acute pain. 9 Perioperative lidocaine infusions can attenuate hyperalgesic responses to nociceptive stimuli and may reduce the development of chronic pain. 10, 11 Prior small randomized clinical trials have demonstrated a pronounced effect of intraoperative lidocaine on persistent postsurgical pain after breast surgery. [12] [13] [14] These studies assessed pain using a yes/no scoring system and did not utilize the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) recommendations to evaluate persistent pain. 15 IMMPACT is a consortium of researchers and practitioners in pain medicine whose mission is to develop consensus reviews and recommendations for improving the design, execution, and interpretation of clinical trials of treatments for pain.
IMMPACT recommendations for assessment of chronic postsurgical pain include not only evaluation of the presence or absence of pain, but also evaluation of the clinical meaningfulness of the pain, the level of pain at rest and with movement, the pain qualities, and the effect of pain on physical and emotional functioning. [16] [17] [18] The main objective of the current study was to assess the efficacy of intravenous (IV) lidocaine in reducing persistent postsurgical pain following breast cancer surgery using validated pain instruments in accordance with the IMMPACT recommendations. Because prior studies have utilized a single yes/no response and have not evaluated the clinical meaningfulness of pain, we hypothesized that IV lidocaine would reduce persistent pain after mastectomy, but the clinical effect size would be smaller than that reported in prior studies.
MATERIALS AND METHODS

Study Design
The study was approved by the Northwestern University Institutional Review Board (STU00061676; Chicago, IL), and the trial was prospectively registered at ClinicalTrials.gov (NCT01619852). Adult females 18 to 70 years of age undergoing breast cancer surgery at Prentice Women's Hospital (unilateral or bilateral mastectomy with or without lymph node involvement) were recruited to participate. Exclusion criteria included patient declining to participate, nonfluent in English, history of cardiac arrhythmias, American Society of Anesthesiologists physical status classification of 4 or greater, history of allergy to amide local anesthetics, opioid-tolerant subjects (30 mg of oral morphine equivalents for > 3 months), history of other previous chronic pain conditions, presence of infection, or pregnancy.
Subjects were approached by a study team member in the preoperative anesthesia area, explained the details of the study, and allowed to ask questions regarding the study details. Prior to preforming any study procedures, all patients provided written informed consent. Prior to study commencement, subjects were randomized into 2 groups using random block sizes of 2, 4, and 6 and using an R script. 19 Group allocation of random assignments was performed by a single investigator (R.J.M.) not involved in patient recruitment or assessment. Group assignments were placed in a sealed opaque envelope that was opened by a single investigator (G.S.D.) after obtaining written informed consent. Preoperatively, patients were screened for the potential of a depression or an anxiety disorder using the Harvard Department of Psychiatry National Depression Screening Day Scale (HANDS). 20 A score of ≥ 9 was considered a positive screening result suggestive of a major depressive episode or an anxiety disorder.
Patients allocated to Group 1 received 1.5 mg/kg bolus of IV lidocaine followed by a 2 mg/kg/hour infusion, while those in Group 2 received normal saline at the same bolus and infusion rate. The maximum allotted dose of lidocaine administered during the surgical procedure was 1,200 mg. Sealed opaque envelopes were opened preoperatively, and the study medication was prepared by research personnel not involved in clinical care or the evaluation of outcomes. The infusion for both groups was identical, started at the time of anesthesia induction and discontinued 1 hour following placement of the last suture. The anesthesia team and study personnel involved in postoperative assessment were blinded to the study arm.
All patients received an anesthetic regimen consisting of propofol, remifentanil, succinylcholine, and sevoflurane. All patients received ondansetron 4 mg and dexamethasone 4 mg for nausea and vomiting prophylaxis. 21 Remifentanil was administered as an infusion starting at a rate of 0.05 lg/kg/minute and titrated in 0.01 lg/kg/minute increments by the anesthesiologist to maintain blood pressure within 80% of baseline. At the end of surgery, all subjects received hydromorphone 10 lg/kg as part of the pain management protocol.
In the postanesthesia recovery area, patients received IV hydromorphone 0.5 mg titrated to maintain the numerical rating pain score (NRS) of ≤ 4 (0 = no pain, 10 = worst pain imaginable) as assessed by the nursing personnel. Prior to discharge from the postanesthesia care unit, a patient-controlled IV hydromorphone analgesia pump was initiated with patient-activated boluses of 0.2 mg of the same solution with no basal infusion rate and a lockout interval of 15 minutes. Patientcontrolled analgesia was discontinued and patients were given oral hydrocodone/acetaminophen 10/325 mg when the patient was able to tolerate oral medications. No nonsteroidal anti-inflammatory medications or IV acetaminophen were administered during the first 24 hours postoperatively.
Subject and procedural characteristics including tumor type, lymph node involvement, histological grade, operative time, and pain at presentation in an area other than the operative sight were recorded. Patients were visited and evaluated by study personnel over the first 24 hours after surgery. Pain was assessed on an 11-point NRS scale (0 = no pain, 10 = worst pain imaginable) at arrival to recovery area and at 30 minutes, 1 hour, and every 6 hours for the first 24 hours. Pain burden, defined as the area under the numeric rating score for pain for the first 24 hours, was calculated using trapezoidal integration. 22 The amount of opioid analgesics consumed was verified via the electronic medical record and was converted to an equivalent dose of IV morphine. 23 Quality of recovery was assessed at 24 hours using a questionnaire (QoR-40) consisting of 40 questions that examined 5 domains of patient recovery on a 5-point Likert scale: none of the time, some of the time, usually, most of the time, and all of the time. The 5 domains include physical comfort, pain, physical independence, psychological support, and emotional state. 24, 25 All patients were sent validated questionnaires by mail at 3 and 6 months to answer questions regarding the presence, quality, and severity of pain using the Brief Pain Inventory (BPI), 26 To improve the 6-month assessment interval, 2 investigators (M.C.K. and J.M.B.) used more comprehensive methods for follow-up and we were able to contact many of the subjects that we were unable to contact at 3 months.
IMMPACT Questionnaires
The primary outcome of this investigation was the frequency of chronic postsurgical pain as assessed using validated pain instruments in accordance with the IMMPACT recommendations (Table 1) . 15 Chronic pain was assessed in accordance with the IMMPACT recommendations in the domains of (1) absence or presence of pain in the area of the surgery, (2) clinically important (NRS score of ≥ 4 on a 0-to 10-point scale) daily average pain, (3) clinically important pain at rest, (4) clinically important pain intensity upon movement or activity, (5) pain qualities, and (6) physical and emotional functioning. [16] [17] [18] The BPI, which has been validated in cancer patients, was used to determine the outcome measures of pain intensity upon movement and with activity as well as physical and emotional functioning (domains 1 to 4 and 6). 25, 26 The use of these single questions to evaluate pain intensity is supported by the IMMPACT recommendations for assessing pain in clinical trials and by the U.S. Food and Drug Administration Draft Guidance for Industry: PatientReported Outcome Measures. 15, 17, 31, 32 The McGill Pain Questionnaire is a valid, reliable, and sensitive multidimensional measure of chronic pain after mastectomy and cancer pain, and was used to assess pain quality outcome measures impacting both the sensory and affective pain domains (domain 5). 27, 28 The McGill Pain Questionnaire has been shown to produce similarities in the descriptive characteristics of chronic persistent pain following mastectomy, inguinal herniorrhaphy, median sternotomy, and saphenectomy. 33 Prior studies of cancer patients have suggested that a total pain index score of ≥ 12 is associated with chronic cancer pain. 34 The LANSS scale was used to assess a neuropathic mechanism contributing to the pain (score of > 12). 35 Subjects had to meet all 6 outcome domains to fulfill the IMMPACT criteria.
Statistical Analysis
The sample selected for this study was based on the finding of prior studies evaluating the effect of a lidocaine infusion on the occurrence of chronic postsurgical pain.
12-14 A sample of 134 subjects per group was determined to be required to achieve 80% power to detect a difference in the incidence of chronic pain of 30% in the saline group compared with 15% in the lidocaine group at a significance level (alpha) of 0.05 (2-sided) using Fisher's exact test. Sample size calculation was performed using PASS version 11.0. The primary outcome, the incidence of chronic postsurgical pain, was compared between subjects randomized to placebo compared to lidocaine using the Fisher's exact test. Subjects who did not complete the intended intervention were treated as intent-to-treat. The patients' NRS scores in the perioperative area, NRS scores at the nonsurgical site, tumor size, intraoperative remifentanil infusion, and the duration of surgery (minutes) were compared among groups using the Mann-Whitney U Test. The chi-square test with Yates correction was used to compare differences in tumor characteristics, staging, and lymph node involvement. QoR-40 results and those of the subdomains of the QoR questionnaire were Bonferroni-corrected for 5 comparisons. The median difference and the 95% confidence interval (CI) of the difference were calculated using 10,000 bootstrap samples. Data analysis was performed using SPSS version 24.0.0.1 (IBM Corp., Somers, NY, U.S.A.), R version 3. 
RESULTS
Subject flow through the study protocol is shown in Figure 1 . One hundred sixty-two patients were approached to participate, and 150 patients consented for study participation. The participants were recruited from June 2012 to July 2014. Twelve patients refused to participate and were excluded from the randomization. No subject experienced an unanticipated adverse event during the study period. Subjects' baseline, tumor, and surgical procedure characteristics are shown in Table 2 . Patients' baseline and tumor characteristics did not differ between groups. The median (interquartile range) dose of intraoperative remifentanil was less in patients in Group 1, 881 lg (586 to 1,144 lg), compared to Group 2, 1,061 lg (698 to 1,496 lg), difference À180 lg (À356 to À1), P = 0.02.
Follow-up assessments at 24 hours and at 3 and 6 months are shown in Table 3 . At the 24-hour followup assessment, there were no differences in pain burden, opioid consumption, or quality of recovery in patients in either group. At the 3-month follow-up assessment, the response rate was 56% (83/148), with a total of 43 responders form Group 1 and 40 from Group 2. There were no differences in neuropathic pain score, sensory discrimination or motivational-affective dimensions of pain, or total pain descriptors in Group 1 compared to Group 2 patients. The BPI score for total pain, percentage pain relief, or pain interference were not different between groups. At 6 months following surgery, the response rate was 82% (121/148), with a total of 62 responders from Group 1 and 59 from Group 2. There were no differences in neuropathic pain score, sensory discrimination or motivational-affective dimension, total pain score, percentage pain relief, or pain interferences between group.
Assessment of chronic pain using IMMPACT criteria is shown in Table 4 . At 3 months following surgery, 42% of Group 1 and 33% of Group 2 respondents reported pain in the area of the surgery, difference À9% (95% CI À32% to 14%; P = 0.51). Two of 43 patients (5%) in Group 1 and 4 of 40 patients (10%) in Group 2 met all 6 IMMPACT criteria for persistent postsurgical pain, difference 5% (95% CI À19% to 9%; P = 0.35). At 6 months, pain reported in the area of the surgery was 13% compared with 29% in Group 2, difference 16% (95% CI À32% to 0%; P = 0.04). All IMMPACT criteria for the assessment of persistent postsurgical pain were met by 2 of 62 patients (3%) in Group 1 compared with 2 of 59 patients (3%) in Group 2 at the 6-month follow-up assessment, difference 0% (95% CI À8% to 8%; P = 0.96).
DISCUSSION
The important finding of our study is that although IV lidocaine reduced the number of subjects reporting persistent pain in the area of surgery at rest, this intervention was not effective in reducing persistent postsurgical pain at 3 months or 6 months following breast cancer surgery when assessed by validated pain instruments in accordance with the IMMPACT recommendations. Similar to other small randomized trials, we found that systemic lidocaine administration decreased pain in the area of surgery at 6 months using a binary (yes/no) pain assessment. [12] [13] [14] However, when assessing the domains of pain recommended by IMMPACT, it would appear that the effect of lidocaine is primarily on pain at rest and not on pain with activity, pain qualities, or the physical or emotional impact of the pain. Our results suggest the overestimation of the effect of systemic lidocaine in reducing persistent postsurgical pain, and highlight the need to use comprehensive standardized assessment guidelines such as those suggested by IMMPACT in future studies.
Our results are clinically important because the prevalence of chronic postsurgical pain has been considered to occur in up to 60% of women undergoing breast surgery, with no established methods of prevention currently established. 36, 37 To date, systemic lidocaine has been the only strategy confirmed in randomized controlled trials to reduce the incidence of persistent postsurgical pain following breast surgery. Interestingly, the binary yes/no criteria used for assessment in those studies for the assessment of chronic pain would have similarly led to a positive finding in the current investigation.
Prior studies have demonstrated a long-term benefit of a systemic lidocaine infusion despite no difference in perioperative analgesic use. In a randomized controlled trial involving 36 breast cancer patients, Grigoras and colleagues observed a 36% reduction in the presence of pain at 3 months following breast cancer surgery. 13 Likewise, in a secondary analysis double-blind randomized controlled study, Terkawi et al. reported that 4 of 34 patients (12%) in the lidocaine group vs. 8 of 27 (30%) in the placebo group reported persistent pain at 6 months following surgery.
14 No differences in analgesic outcomes in the perioperative period were observed in either of these studies.
Other intraoperative interventions to reduce the incidence of persistent postsurgical pain have been evaluated in randomized clinical trials. Ilfeld et al. 38 demonstrated that a multiple-day, continuous ropivacaine infusion to a single-injection ropivacaine paravertebral nerve block may result in a lower incidence of pain as well as pain-related physical and emotional dysfunction 1 year after mastectomy. Wylde et al. 39 recently demonstrated that routine use of infiltration could be beneficial in improving long-term pain relief for some patients after total hip replacement. Unfortunately, none of those recent investigations of the beneficial effects of preventive analgesia use have used the IMMPACT recommendations to evaluate chronic pain. Another important finding of the current investigation was the overall low incidence of chronic postmastectomy pain when assessed using the IMMPACT criteria compared with the incidence reported in prior investigations. 40 The overall incidence of chronic postmastectomy pain of 4% is substantially lower than the current accepted rates (30% to 60%) of chronic pain following this surgical procedure. 1 The evaluation of postsurgical pain remains a challenging issue because of the subjective experience of pain, and the variability of postsurgical assessments leads to studies reporting conflicting results. In a systematic review of the neuropathic component in persistent postsurgical pain, Haroutiunian et al. 41 demonstrated considerable inconsistencies in the definition and † Calculated using trapezoidal integration of pain score upon arrival to the recovery area and at 30 minutes, 1 hour, and every 6 hours up to 24 hours following the procedure.
‡ Quality of recovery assessed using the Quality of Recovery 40-question (QoR-40) questionnaire at 24 hours following surgery.
§ Numeric rating scale score for pain (0 to 10 scale, where 0 is no pain and 10 is the worst pain imaginable) reported from the Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) questionnaire. Data are presented as medians (interquartile range) or n (%). CI, confidence interval; morEq, morphine equivalents. assessment of persistent postsurgical pain. Moreover, a recent large-scale study demonstrated that the methodology of pain assessment may result in a 50% difference in persistent postsurgical pain reporting in the same patient population. 36 It has also been reported that the pain is not constant: it may either increase or decrease with time, or it may remain for many years after surgery. Taken together, our findings reaffirm the importance of using standardized criteria, such as those recommended by IMMPACT, when assessing interventions to mitigate persistent postsurgical pain. Use of standardized assessment methods will allow for more direct comparison of chronic pain prevention strategies and facilitate metaanalysis of studies examining additional meaningful clinical outcomes such as pain burden and disruption of quality of life related to the chronic pain.
Our study should only be interpreted within the context of its limitations. The protocol for this study was developed to assess the 6 core domains for recovery from surgical pain as described in the IMMPACT recommendation for chronic pain clinical trials in 2005. 16 IMMPACT did not specifically designate which assessment tools would be the most specific for examining the 6 categories of outcome assessments in their recommendations, and we designated the association between the instruments used and the recommended areas of assessment. Although we used validated assessment tools to apply IMMPACT criteria for the evaluation of persistent postsurgical pain, a different result may have been found if other instruments had been used. We used self-reporting assessment measures without clinical examinations, which may have over-or underestimated the physical functional activity. However, these validated pain instruments are used frequently in assessing pain outcomes in clinical trials. Subsequent to the completion of this trial, IMMPACT recommended design consideration for chronic pain intervention trials and we used the schema proposed in that recommendation to report the results of our study.
15
Previous evidence has shown that a higher dose of remifentanil may yield worse persistent postsurgical pain outcomes. 42 Remifentanil infusions of > 0.1 lg/ kg/minute have been associated with acute opioid tolerance and opioid-induced hyperalgesia, although there is insufficient evidence to evaluate if these effects of remifentanil directly contribute to chronic persistent pain. 43 Nonetheless, the difference found in intraoperative remifentanil dosing among groups may be a confounding factor for the development of persistent postsurgical pain at 6 months. We only evaluated the impact of systemic lidocaine on chronic postmastectomy pain; therefore, we cannot generalize our findings to other types of surgeries with greater incidence of postsurgical pain (eg, thoracotomy). All the patients in this study underwent other interventions, radiation, and/or chemotherapy and may have had reconstructive procedures that may have impacted the incidence of chronic postsurgical pain in this population. We terminated our study after only 150 subjects had been enrolled based on futility using our original outcomes estimates. Therefore, our findings of a lack of benefit of IV lidocaine is made with somewhat high uncertainty due to the limited power of our sample. Finally, we assessed all areas of pain characteristics based on the IMMPACT statement, and not all of these may show benefit from a single intervention designed to reduce persistent postsurgical pain. Future studies to evaluate multimodal analgesic interventions that effect other aspects of persistent postsurgical pain are warranted.
Similar to prior studies, we found a beneficial effect of intraoperative systemic lidocaine on the prevalence of persistent postmastectomy pain at 6 months using a yes/ no response. However, when assessed using IMMPACT criteria, we detected a much lower incidence of chronic postmastectomy pain than prior studies. The use of a stricter definition of chronic pain as recommended by the IMMPACT guidelines likely explains the differences obtained in the current study when compared to prior investigations. Future studies that evaluate interventions on chronic postsurgical pain should adhere to the IMMPACT recommendations in order to reduce methodological variability and to better understand the relative benefit of the intervention on study outcomes.
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